Methods
* a multi-center, double-blind, placebo-controled, randomized study ( 4 tertiary hospital ED)
* survey for the occurrence of vomiting at ED and after discharge
Primary outcome
* the number of vomiting at ED and at home
Secondary outcome
* parent's satisfaction and ED length of stay
Age
0–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
children under 18 years of age
children who are planned to admit ketamine intramuscular injection
children with ASA classification class I or II
You may not be if
don't want to enroll to study
children with condition of contraindication of ketamine (IICP, IIOP, psychosis, brain tumor, thyroid disease, porphyria)
children with condition of contraindication of ondansetron (hypersensitivity to 5-HT3 antagonist, Long QT syndrome, severe liver failure, obstructive ileus)
